ACE-Inhibitory Peptides in Food and Blood Pressure
Food-Derived Bioactive Peptides
1,700+ peptides
The Database of Antihypertensive Peptides contains over 1,700 unique ACE-inhibitory peptides identified from food sources including milk, fish, soy, and grains.
Li et al., Foods, 2025
Li et al., Foods, 2025
View as imageEvery time you eat cheese, drink milk, or consume fermented soy, your digestive system breaks proteins into smaller peptide fragments. Some of these fragments have a specific biological activity: they inhibit angiotensin-converting enzyme (ACE), the same enzyme targeted by prescription drugs like lisinopril and captopril. The pharmaceutical connection is not coincidental. Captopril, the first ACE inhibitor, was developed from a peptide found in Brazilian pit viper venom. The same enzyme target exists in food-derived peptides, though with far weaker potency. For background on how antioxidant peptides from food function as bioactive compounds, see our pillar article on food-derived peptides.
Over 1,700 unique ACE-inhibitory peptides have been identified from food sources. A 2025 randomized controlled trial showed that casein-derived ACE-inhibitory peptides reduced systolic blood pressure by 9.4% and diastolic pressure by 9.5% in prehypertensive and hypertensive participants.[1] This article covers what ACE-inhibitory food peptides are, where they come from, how strong the evidence is, and what limits their practical application.
Key Takeaways
- Over 1,700 ACE-inhibitory peptides have been identified from food sources including milk, fish, soy, grains, and eggs
- A 2025 RCT showed casein-derived peptides reduced systolic blood pressure by 9.4% and reshaped gut microbiota (Li et al., Scientific Reports)
- The most studied food ACE-inhibitors are the lactotripeptides VPP and IPP from fermented milk
- ACE-inhibitory peptides are typically under 3 kDa with hydrophobic amino acids at the C-terminal end
- Bioavailability remains the central challenge: most peptides are degraded during digestion before reaching the bloodstream
- Machine learning is accelerating discovery, with AI identifying novel antihypertensive peptides from barley, mushroom, and amaranth proteins
How ACE-Inhibitory Peptides Work
ACE (angiotensin-converting enzyme) is a zinc metallopeptidase that plays a central role in blood pressure regulation through the renin-angiotensin system (RAS). ACE converts the inactive decapeptide angiotensin I into angiotensin II, a potent vasoconstrictor that raises blood pressure. ACE also degrades bradykinin, a vasodilator. By inhibiting ACE, these peptides reduce angiotensin II production and preserve bradykinin levels, producing a net blood-pressure-lowering effect.
Li et al. reviewed the mechanisms of action of food-derived ACE-inhibitory peptides and identified three distinct inhibition modes.[2] Competitive inhibition, where the peptide competes with angiotensin I for the ACE active site, is the most common. Non-competitive and uncompetitive inhibition also occur, where peptides bind to allosteric sites on the enzyme. The specific mode depends on the peptide's amino acid sequence and its interaction with the zinc ion and substrate-binding pockets at the ACE catalytic site.
Guo et al. expanded this picture beyond ACE inhibition, documenting that food-derived antihypertensive peptides can also act through calcium channel blocking, endothelin-1 suppression, nitric oxide pathway activation, and renin inhibition.[3] This multi-target potential distinguishes food peptides from single-target pharmaceutical ACE inhibitors, though the clinical relevance of these additional mechanisms in food-derived peptides has not been established in humans.
Where ACE-Inhibitory Peptides Come From
ACE-inhibitory peptides are not synthesized. They are released from food proteins during enzymatic hydrolysis, fermentation, or gastrointestinal digestion. The parent protein determines which peptides are produced.
Milk and Dairy
Casein and whey proteins are the most extensively studied sources. The lactotripeptides VPP (Val-Pro-Pro) and IPP (Ile-Pro-Pro), produced during milk fermentation by Lactobacillus helveticus, are the most researched ACE-inhibitory food peptides globally. They have been commercialized in Japan (Calpis/Ameal) and Finland (Evolus).
Iwaniak et al. reviewed bovine milk protein-derived preparations and their hydrolysates as sources of ACE-inhibitory peptides, documenting that both casein fractions (alpha-s1, alpha-s2, beta, kappa) and whey proteins (beta-lactoglobulin, alpha-lactalbumin) produce ACE-inhibitory sequences during enzymatic digestion.[4] Kapoor et al. reviewed the broader nutraceutical potential of bioactive milk peptides, noting that fermentation conditions (bacterial strain, temperature, duration) significantly affect which ACE-inhibitory peptides are produced and at what concentrations.[5]
Casomorphins, the opioid peptides found in cheese, are a different class of milk-derived bioactive peptides. Both casomorphins and ACE-inhibitory peptides can be produced from the same parent casein protein, but they have distinct biological activities and different amino acid sequences.
Fish and Seafood
Fish muscle proteins, skin collagen, and visceral organs are rich sources of ACE-inhibitory peptides. Han et al. identified ACE-inhibitory peptides from crucian carp that demonstrated in vivo antihypertensive activity in spontaneously hypertensive rats, with blood pressure reductions confirmed after oral administration.[6] Marine sources are particularly interesting because fish collagen hydrolysates contain high proportions of proline and hydroxyproline, amino acids that are frequently found at the C-terminal position of potent ACE-inhibitory peptides.
Plant Proteins
Soy, wheat, rice, barley, and amaranth proteins all produce ACE-inhibitory peptides upon hydrolysis or fermentation. Nardo et al. characterized multitarget peptides from amaranth that inhibited both ACE and modulated ACE2, a related enzyme with opposing effects in the RAS system, and assessed their bioavailability using in vitro digestion models.[7] Bao et al. used machine learning to discover novel antihypertensive peptides from highland barley protein, identifying candidates that inhibit both ACE and renin, the enzyme upstream of ACE in the RAS pathway.[8]
Novel Sources
AI-assisted discovery is expanding the source catalog. Chen et al. used artificial intelligence to identify dual antioxidant and ACE-inhibitory peptides from Hericium erinaceus (lion's mane mushroom), a source not traditionally associated with cardiovascular bioactivity.[9] This kind of computational screening, followed by in vitro validation, is accelerating the identification of ACE-inhibitory peptides from underexplored protein sources.
Clinical Evidence: What Human Trials Show
The most important question is whether eating food-derived ACE-inhibitory peptides actually lowers blood pressure in humans. The answer is: yes, but modestly.
The strongest clinical evidence comes from the lactotripeptides VPP and IPP. Multiple randomized controlled trials in Japanese and European populations have shown small but statistically significant reductions in systolic blood pressure (typically 3-5 mmHg) with daily consumption of fermented milk products containing these peptides. The effect is modest compared to pharmaceutical ACE inhibitors (which typically reduce SBP by 8-15 mmHg) but is consistent across trials.
The most recent RCT by Li et al. tested casein-derived ACE-inhibitory peptides (specifically GPFPIIV and FFVAPFPEVFGK) in prehypertensive and hypertensive participants. After 8 weeks, systolic blood pressure decreased by 9.41% and diastolic by 9.53% in the treatment group. The study also found that the peptide treatment reshaped gut microbiota composition, suggesting a second mechanism of blood pressure regulation beyond direct ACE inhibition.[1]
These reductions are clinically meaningful at the population level. A sustained 5 mmHg reduction in SBP is associated with approximately 10% lower risk of major cardiovascular events. But individual responses vary substantially, and the effect sizes from food-derived peptides are consistently smaller than from pharmaceutical ACE inhibitors. Food peptides are not replacements for medication in patients with established hypertension.
The Bioavailability Problem
The central limitation of food-derived ACE-inhibitory peptides is bioavailability. A peptide that potently inhibits ACE in a test tube may be completely degraded during gastrointestinal digestion before it reaches the bloodstream.
Du et al. studied the transport and action of sesame protein-derived ACE-inhibitory peptides ITAPHW and IRPNGL, tracing their absorption through intestinal epithelial cell models and documenting how much intact peptide survives transit through the gut wall.[10] The findings illustrate the consistent challenge: the same proteases that release ACE-inhibitory peptides from food proteins also continue to degrade those peptides into smaller, inactive fragments.
Several structural features promote survival during digestion. Peptides containing proline residues resist cleavage by many digestive proteases. Short peptides (2-5 amino acids) are more likely to survive intact than longer sequences. Hydrophobic amino acids at the C-terminus enhance both ACE-binding affinity and resistance to carboxypeptidase degradation.
Liang et al. applied rational design to engineer ACE-inhibitory peptides with enhanced activity through strategic module substitution, modifying specific amino acid positions to improve both potency and stability.[11] This approach bridges the gap between natural food peptides and designed pharmaceutical agents: using food-derived sequences as starting points but optimizing them for better bioavailability and ACE-binding kinetics.
For the broader challenge of protecting peptides during digestion, see Peptide Encapsulation in Food Technology: Protecting Bioactivity Through Digestion. For the path from research to commercial products, see Bioactive Peptides as Functional Food Ingredients: From Lab to Shelf.
Limitations of the Current Evidence
The research on food-derived ACE-inhibitory peptides is extensive but uneven.
In vitro potency does not predict in vivo efficacy. The IC50 values measured in test-tube ACE inhibition assays do not account for digestion, absorption, distribution, or metabolic clearance. A peptide with a low IC50 may never reach the ACE enzyme in the body.
Most studies are animal models. While hundreds of ACE-inhibitory peptides have been characterized in vitro, only a small fraction have been tested in animal models of hypertension, and fewer still in human clinical trials. The spontaneously hypertensive rat (SHR) is the standard animal model, but SHR blood pressure physiology differs from human essential hypertension.
Effect sizes are small. Even in positive clinical trials, the blood pressure reductions from food peptides (3-10 mmHg) are smaller than from pharmaceutical ACE inhibitors. This limits their clinical utility for patients who need substantial blood pressure reduction.
Dose-response relationships are unclear. It is difficult to standardize the ACE-inhibitory peptide content of fermented or hydrolyzed food products. The amount of active peptide varies with protein source, processing conditions, fermentation time, and bacterial strain. This makes it hard to establish clear dose-response curves.
Gut microbiota effects are newly recognized. The Li et al. RCT finding that casein peptides reshape gut microbiota composition raises the possibility that some blood pressure effects are mediated through the gut rather than direct ACE inhibition. Specific bacterial genera associated with short-chain fatty acid production increased during the intervention, and short-chain fatty acids have independent blood-pressure-lowering effects. If a substantial portion of the clinical benefit comes through microbiome modulation rather than direct ACE inhibition, the in vitro ACE inhibition assay would be measuring the wrong endpoint for the clinical effect. This could explain why some peptides with strong in vitro ACE inhibition show disappointing results in clinical trials: the wrong mechanism is being optimized. For the broader role of gut peptide hormones in signaling, the gut-blood pressure axis is an emerging area of research.
These limitations do not invalidate the research. ACE-inhibitory food peptides are real, measurable, and functionally relevant. But the gap between in vitro potency screening and clinical blood pressure reduction remains wide.
Related Peptides in Blood Pressure Regulation
ACE-inhibitory peptides are one piece of the blood pressure puzzle. The body produces endogenous peptides that regulate blood pressure through complementary pathways. ANP (atrial natriuretic peptide) is released by the heart in response to atrial stretching and lowers blood pressure by promoting sodium excretion and vasodilation. Melanocortin peptides have the opposite effect, raising blood pressure through central nervous system mechanisms. Understanding how food-derived peptides interact with these endogenous systems is an active area of investigation.
The Bottom Line
Food-derived ACE-inhibitory peptides are biologically active compounds released from milk, fish, soy, and grain proteins during digestion, fermentation, or enzymatic hydrolysis. Over 1,700 have been identified. Clinical trials show modest but real blood pressure reductions (3-10 mmHg), with the strongest evidence for milk-derived lactotripeptides VPP and IPP. Bioavailability remains the central limitation: most peptides are degraded during digestion before reaching the bloodstream. AI-driven discovery and rational peptide design are accelerating identification of more potent, more stable candidates.